Business
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
CAMBRIDGE, Mass., January 29, 2026--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that its subsidiary, Akos Biosciences, has licensed to TOTEC Pharma, Inc. ("TOTEC") its US Trademark portfolio for RCANN™ and an RCANN™ design. TOTEC, an affiliate of Aries Science & Technology ("Aries"), is advancing the commercialization o
About this update from Enveric Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/7fd25894edf31fe8c35e72f2eb102be4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9mCQzyQxFzKho0odA46nNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7fd25894edf31fe8c35e72f2eb102be4","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/uTa5PyAjsYzAphcTWwddaw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/7fd25894edf31fe8c35e72f2eb102be4","width":1024,"height":512}},"lazy":false},{"type":"text","content":"RCANN™ Trademark Portfolio Out-Licensed","length":39,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., January 29, 2026--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that its subsidiary, Akos Biosciences, has licensed to TOTEC Pharma, Inc. ("TOTEC") its US Trademark portfolio for RCANN™ and an RCANN™ design. TOTEC, an affiliate of Aries Science & Technology ("Aries"), is advancing the commercialization of patented cannabinoid crème technology created by Enveric and intended for use in treatment of radiation dermatitis. The trademark license to TOTEC includes an option to purchase the RCANN trademark portfolio in the future, contingent on TOTEC meeting certain development and commercialization milestones.","length":867,"tagName":"p"},{"type":"text","content":""We are pleased that TOTEC has chosen to further license the RCANN trademark portfolio in connection with advancing the licensed cannabinoid technology towards commercialization," said Joseph Tucker, PhD, CEO of Enveric. "We believe that this trademark license enhances the value to both parties of the patented cannabinoid technology previously licensed to the TOTEC affiliate, Aries, that is now being advanced by TOTEC." Dr. Tucker added, "This license further extends the business development momentum of Enveric which has been aided by the out-licensing of non-core ...